Join our Community
Support ToI and remove all ads
Learn more
search
Dr. Tal Zaks
Illustrative: Thabisle Khlatshwayo receives her second shot at a vaccine trial facility for AstraZeneca at Soweto's Chris Sani Baragwanath Hospital outside Johannesburg, South Africa, November 30, 2020. (AP Photo/Jerome Delay)
January 6, 2021, 11:16 pm
Health official: ‘Worrying’ study on vaccine’s potency against S. African strain
Sharon Alroy-Preis says unclear what impact vaccination has on COVID variant, but warns it may offer less protection against mutation
By TOI staff
University of Miami Miller School of Medicine lab technician processing blood samples from study participants who volunteered to take part in testing the National Institutes of Health-funded Moderna COVID-19 vaccine in Miami, September 2, 2020. (AP Photo/Taimy Alvarez, File)
November 30, 2020, 3:12 pm
Moderna seeks US, EU approval for vaccine as final results show 94% efficacy
‘I allowed myself to cry for the first time’ when learning of the results, says Israeli chief medical officer as pharma firm asks regulators to allow emergency use of the jab
By Agencies and TOI staff
A syringe and a vial with the logo of US biotech firm Moderna. (AFP)
November 17, 2020, 12:20 am
With new vaccine technology, small biotech firm Moderna battles mighty pandemic
Massachusetts-based company saw share price soar after announcing its coronavirus vaccine is 94.5% effective. Bullish CEO, promising up to a billion doses, says it’s just the start
By AFP and TOI staff
Moderna's Chief Medical Officer Dr. Tal Zaks. (Screenshot: YouTube)
November 16, 2020, 6:41 pm
Moderna’s top medical officer says Israel will be among first to get vaccine
It’s ‘around the corner,’ says Tal Zaks, who is Israeli, estimating that shots will reach Jewish state early next year
By TOI staff and Agencies
An entrance to a Moderna, Inc., building, May 18, 2020, in Cambridge, Massachusetts. (AP Photo/Bill Sikes)
May 28, 2020, 3:21 am
Amid virus vaccine hopes, Moderna top execs said to have sold millions in stocks
US biotech firm’s shares soared when it claimed progress in trials; analysts say sales, including by Israeli chief medical officer, are legal but undermine faith in company
By TOI staff and Agencies
In this March 16, 2020, file photo, a pharmacist gives Jennifer Haller, left, the first shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19, the disease caused by the new coronavirus, at the Kaiser Permanente Washington Health Research Institute in Seattle. The vaccine by Cambridge, Massachusetts-based Moderna Inc., generated antibodies similar to those seen in people who have recovered from COVID-19 in a study volunteers who were given either a low or medium dose. (AP Photo/Ted S. Warren, File)
May 18, 2020, 9:04 pm
Moderna’s Israeli top medical officer: We’ve shown today that our vaccine works
US biotech firm’s shares soar as it claims tests of first volunteers show its vaccine candidate produces immune response, ‘has potential to prevent COVID-19’; Phase 3 tests in July
By TOI staff and Agencies
Load More